Over 2, phase 3 studies, brexpiprazole-treated patients demonstrated greater response rates across various levels on the Cohen-Mansfield Agitation Index and Clinical Impression Scale-Improvement assessment.

Combination of atogepant and ubrogepant resulted in minimal adverse events, and were safe and well-tolerated over a 12-week period.

Results showed consistent reductions in monthly migraine days over 48 weeks, with a favorable safety profile observed.

Here's some of what is coming soon to NeurologyLive® this week.

Even at the highest modal dose range, findings from the phase 3 RISE-PD trial showed that IPX203 did not increase safety risks for patients with Parkinson disease over time.

New findings from the phase 3 PROOF-HD trial showed that pridopidine outperformed placebo up to 78 weeks in patients with Huntington disease even after excluding those on neuroleptics and antichorea medications.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the American Academy of Neurology Annual Meeting.

Patients on riliprubart demonstrated improvements on several measures of disability and impairment, including the INCAT, I-RODS, MRC-SS, and grip strength.

Patients with first MS symptoms less than 3 years prior to enrollment saw greater long-term benefits with ublituximab than those with longer disease course.

In the phase 3 MOMENTUM and INTERCEPT studies, patients treated with AXS-07 saw reductions in headache pain freedom, most bothersome symptoms, and use of rescue medications.

Being a boy, having lower depression and anxiety scores, lower headache intensity, lower affective pain perception, fewer pain locations, fewer sleep issues, and lower pain-related disability predicted headache remission.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 12, 2024.

ALKS 2680, an investigational orexin 2 receptor agonist, showed promise for improving sleep latency in patients with narcolepsy type 2 and idiopathic hypersomnia in a phase 1b study.

Analyzing data from the H70-BCS, researchers identified around 6.2% of 70-year-olds meeting lecanemab treatment criteria, suggesting millions in Europe and the US might be eligible.

All 8 participants met prespecified responder criteria demonstrating either improvement or stabilization of disease according to both the Patient Reported Global Impression of Change and the Clinician Reported Global Impression of Change scales.

At 180 days after surgery, weighted disability scores were better with surgery plus medical management than with medical management alone.

The FDA has approved a label update on the administration options for SK Life Science’s cenobamate, a treatment approved for adults with partial-onset seizures.

The smartphone tests accurately differentiated individuals with dementia from controls and were more sensitive to early symptoms than the Montreal Cognitive Assessment, a commonly used cognitive screening tool.

The new double-blind, placebo-controlled study includes approximately 200 patients with ALS who will undergo a single bone marrow aspiration procedure to procure the mesenchymal stem cells that will be used to manufacture each participant’s NurOwn treatment for the trial.

The executive vice president and chief research officer of the Muscular Dystrophy Association shared her reaction to the recent FDA approval of givinostat for Duchenne muscular dystrophy.

The first patient enrolled into the phase 1/2a ArthemiR trial assessing ATX-01 myotonic dystrophy type 1 is expected in the second quarter of 2024.

The new position statement proposes the use of CGRP-targeting therapies to be used as first-line treatments, eliminating the need to fail multiple medications before access.

The newly initiated phase 3 trial follows a successful phase 2 study where treatment with pitolisant resulted in greater improvement on the Epworth Sleepiness Scale for Children and Adolescents than placebo.

Sleeping Around the Podcast × NeurologyLive brings you a clinical overview of a newly published study highlighting extracellular vesicle-associated miRNA features that could be diagnostically informative of RBD in patients with Parkinson disease.

The newly cleared i-STAT TBI test can be used to help assess patients up to 24 hours after injury at patient bedside, with lab-quality results produced in 15 minutes.